Evidence map›Paper›PMID 8880912›Full record

ArticleProtein science : a publication of the Protein Society1996

Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va.

M J Heeb, Y Kojima, T M Hackeng, J H Griffin

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Protein C anticoagulant and cytoprotective pathways.International journal of hematology · 2012
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

M J HeebDepartment of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037, USA. heeb@scripps.edu
Y Kojima
T M Hackeng
J H Griffin
Scripps Research Institute · US

Funding

Structure and Function of Protein CR01HL052246 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GRIFFIN, JOHN H · 2005 to 2017
$9.6M
PROTEINS OF COAGULATION PATHWAYSR01HL021544 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GRIFFIN, JOHN H · 1985 to 2014
$7.5M
STRUCTURE/FUNCTION OF PROTEIN CR37HL052246 · NHLBI · SCRIPPS RESEARCH INSTITUTE · PI GRIFFIN, JOHN H · 1995 to 2004
$2.9M
NHLBI NIH HHS HL21544NHLBI NIH HHS HL52246
6 · The paper itself

Abstract

Inactivation due to cleavage of Factor Va (FVa) at Arg 506 by activated protein C (APC) helps to downregulate blood coagulation. To identify potential functional roles of amino acids near Arg 506, synthetic overlapping pentadecapeptides comprising FVa heavy chain residues 481-525 were tested for their ability to inhibit prothrombin activation by prothrombinase complexes [Factor Xa (FXa):FVa:phospholipids:Ca2+]. The most potent inhibition was observed for peptide VP493 (residues 493-506), with 50% inhibition at 2.5 microM. VP493 also inhibited FXa in plasma in FXa-1-stage clotting assays by 50% at 3 microM. When the C-terminal carboxamide group of VP493 was replaced by a carboxyl group, most prothrombinase inhibitory activity was lost. VP493 preincubated with FXa inhibited prothrombinase with a pattern of mixed inhibition. Homologous peptides from Factor VIII sequences did not inhibit prothrombinase. Affinity-purified antibodies to VP493 inhibited prothrombinase activity and prolonged FXa-1-stage clotting times. VP493 also blocked the ability of protein S to inhibit prothrombinase independently of APC. Immobilized VP493 bound specifically with similar affinity to both FXa and protein S (Kd approximately 40 nM), but did not measurably bind prothrombin or APC. These studies suggest that FVa residues 493-506 contribute to binding sites for both FXa and protein S, providing a rationale for the ability of protein S to negate the protective effect of FXa toward APC cleavage of FVa. Possible loss of this FVa binding site for FXa due to cleavage at Arg 506 by APC may help explain why this cleavage causes 40% decrease in FVa activity and facilitates inactivation of FVa.

Indexed as

Amino Acid SequenceAntibodiesAnticoagulantsBinding SitesEnzyme InhibitorsFactor VaFactor XaFactor Xa InhibitorsHumansMolecular Sequence DataPeptide FragmentsProtein SThromboplastinAntibodiesAnticoagulantsEnzyme InhibitorsFactor VaFactor XaFactor Xa InhibitorsPeptide FragmentsProtein SThromboplastin

Identifiers

PMID8880912
PMCPMC2143529
OpenAlexW2163704858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.